Glaxosmithkline’s debt ratios increased over the years, with the debt-to-equity ratio reaching concerning levels in 2015. This suggests that the company has taken on a substantial amount of debt that may be difficult to manage. The time interest earned ratio also raises concerns about GSK’s ability to cover interest payments.